Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are molecular targets of great clinical interest in lung cancer. In particular, its ability to permit clinical efficacy of specific therapies with tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) has been stressed [1, 2].
Exhaled breath condensate is not suitable to detect EGFR somatic mutations
Tommasi S.;Carpagnano G. E.;
2008-01-01
Abstract
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) are molecular targets of great clinical interest in lung cancer. In particular, its ability to permit clinical efficacy of specific therapies with tyrosine kinase inhibitors (i.e. gefitinib or erlotinib) has been stressed [1, 2].File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
